Is long-acting repeatable octreotide an effective primary therapy for patients with acromegaly?

被引：0
|
作者：
Vivien S Bonert
机构：
[1] David Geffen School of Medicine,VS Bonert is a Professor in the Department of Medicine at Cedars Sinai Medical Center
[2] University of California,undefined
[3] Los Angeles,undefined
[4] CA,undefined
[5] USA.,undefined
来源：
Nature Clinical Practice Endocrinology & Metabolism | 2008年 / 4卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：18 / 19
页数：1
相关论文
共 50 条
  • [1] Is long-acting repeatable octreotide an effective primary therapy for patients with acromegaly?
    Bonert, Vivien S.
    NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2008, 4 (01): : 18 - 19
  • [2] Octreotide long-acting repeatable for acromegaly
    Cozzi, Renato
    Attanasio, Roberto
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2012, 5 (02) : 125 - 143
  • [3] Octreotide Long-Acting Repeatable in Acromegaly Achieving Optimal Control
    Cook, David M.
    ENDOCRINOLOGIST, 2009, 19 (03): : 142 - 147
  • [4] A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
    Mercado, Moises
    Borges, Fatima
    Bouterfa, Hakim
    Chang, Tien-Chun
    Chervin, Alberto
    Farrall, Andrew J.
    Patocs, Attila
    Petersenn, Stephan
    Podoba, Jan
    Safari, Mitra
    Wardlaw, Joanna
    CLINICAL ENDOCRINOLOGY, 2007, 66 (06) : 859 - 868
  • [5] Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naive to radiation and medical therapy
    Ghigo, E.
    Biller, B. M. K.
    Colao, A.
    Kourides, I. A.
    Rajicic, N.
    Hutson, R. K.
    De Marinis, L.
    Klibanski, A.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2009, 32 (11) : 924 - 933
  • [6] Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients
    Woltering, Eugene A.
    Salvo, Vergilio A.
    O'Dorisio, Thomas M.
    Lyons, John, III
    Li, Gang
    Zhou, Ying
    Seward, Jacky R.
    Go, Vay Liang W.
    Vinik, Arthur I.
    Mamikunian, Paris
    Mamikunian, Gregg
    PANCREAS, 2008, 37 (01) : 94 - 100
  • [7] Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy
    E. Ghigo
    B. M. K. Biller
    A. Colao
    I. A. Kourides
    N. Rajicic
    R. K. Hutson
    L. De Marinis
    A. Klibanski
    Journal of Endocrinological Investigation, 2009, 32 : 924 - 933
  • [8] Serum ghrelin levels in acromegaly: Effects of surgical and long-acting octreotide therapy
    Freda, PU
    Reyes, CM
    Conwell, IM
    Sundeen, RE
    Wardlaw, SL
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (05): : 2037 - 2044
  • [9] Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients
    van Thiel, SW
    Romijn, JA
    Biermasz, NR
    Ballieux, BEPM
    Frölich, M
    Smit, JWA
    Corssmit, EPM
    Roelfsema, F
    Pereira, AM
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2004, 150 (04) : 489 - 495
  • [10] Comments on "Clinical Value of Monitoring Plasma Octreotide Levels During Chronic Octreotide Long-Acting Repeatable Therapy in Carcinoid Patients"
    Schran, Horst F.
    Hager, Douglas F.
    PANCREAS, 2008, 37 (03) : 334 - 336
12345